MDAI

Spectral AI, Inc. (MDAI) - Q1 2025 10-Q Summary

Business Context and Reporting Period

Spectral AI, Inc. is an emerging growth company and smaller reporting company focused on predictive medical diagnostics using its DeepView System, an AI-powered multispectral imaging device for burn wound assessment. The company currently generates revenue primarily through government research and development contracts, specifically with the Biomedical Advanced Research and Development Authority (BARDA) and the Medical Technology Enterprise Consortium (MTEC). It has not yet generated product revenue. This report covers the quarterly period ended March 31, 2025.

Key Financial Metrics

Note: Net income for Q1 2025 includes a significant non-cash gain of $4.25 million from the change in fair value of warrant liabilities.

Material Changes vs. Prior Period

• Profitability Turnaround: The company reported a net income of $2.90 million compared to a net loss of $3.21 million in the prior year. This swing is primarily driven by a $4.25 million non-cash gain from the change in fair value of warrant liabilities, following a repricing of public warrants in November 2024.
• Revenue Growth: Research and development revenue increased 6.0% to $6.71 million, driven by continued activity under the BARDA contract. 95% of revenue is derived from a single U.S. government agency.
• Expense Reduction: General and administrative expenses decreased 20.1% to $4.06 million, attributed to reduced staffing and consulting costs as the company focused on the DeepView Burn application.
• Liquidity and Debt: Cash balances increased by $8.9 million to $14.1 million. This was fueled by a new $8.5 million debt drawdown from Avenue Capital Group and $2.7 million in equity proceeds, partially offset by the repayment of $2.4 million in Yorkville convertible notes.

Guidance, Outlook, and Risks

• Regulatory Milestones: The company received UKCA marking for its burn indication in February 2024 and anticipates initial sales in the UK in 2025. It is preparing a De Novo application with the FDA for Class II medical device designation in the U.S.
• Financing Milestones: The new Avenue Capital financing includes a second tranche of $6.5 million contingent upon FDA clearance of the DeepView System and the completion of a $7.0 million equity raise.
• Liquidity Outlook: Management believes current cash, government contracts, and the Avenue financing provide sufficient working capital for at least one year beyond the filing date.
• Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to the financial statement close process, which remains unremediated as of March 31, 2025.
• Risks: Key risks include dependence on government contracts (95% concentration), the need for additional capital, supply chain disruptions, and the volatility of reported earnings due to fair value adjustments on warrant liabilities.

Investor Verification Checklist

• Non-GAAP vs. GAAP: Verify the sustainability of the Q1 2025 net income by excluding the $4.25 million non-cash warrant liability gain; the underlying Adjusted EBITDA remains negative at $(0.69) million.
• Debt Covenants: Review the specific milestones required to unlock the remaining $6.5 million tranche of the Avenue Capital facility (FDA clearance and $7M equity raise).
• Customer Concentration: Assess the risk associated with 95% of revenue and receivables coming from a single U.S. government agency (BARDA).
• Internal Controls: Monitor the progress of the remediation plan for the disclosed material weakness in financial reporting controls.
• Warrant Liability: Understand how future fluctuations in the company's stock price will impact the fair value of outstanding warrants and consequently the volatility of reported net income.